Reports

Ideas That Generate Results

List of Figures:

Figure 3-1: Global - Number of New Cancer Cases (Million), 2012 & 2025
Figure 3-2: Global - Cancer Incidences by Gender (Million), 2012
Figure 3-3: Global - Cancer Drugs Market (Billion US$), 2008-2013
Figure 3-4: Global - Cancer Drugs Market (Billion US$), 2014-2018
Figure 3-5: Cancer Drugs Market Share by Geography (%), 2013
Figure 3-6: Cancer Drugs Market Share by Geography (%), 2018
Figure 3-7: Global - Cancer Treatment Modalities Revenue Share (%), 2013
Figure 4-1: Global - Cancer Generics Market (Billion US$), 2013-2018
Figure 6-1: Global - Number of New Lung Cancer Cases (Million), 2012 & 2020
Figure 6-2: Global - Forecast for New Lung Cancer Cases by Region (%), 2020
Figure 6-3: Global - Number of New Breast Cancer Cases (Million), 2012 & 2020
Figure 6-4: Global - Forecast for New Breast Cancer Cases by Region (%), 2020
Figure 6-5: Global - Number of New Colorectal Cancer Cases (Million), 2012 & 2020
Figure 6-6: Global - Forecast for New Colorectal Cancer Cases by Region (%), 2020
Figure 6-7: Global - Number of New Stomach Cancer Cases (Million), 2012 & 2020
Figure 6-8: Global - Forecast for New Stomach Cancer Cases by Region (%), 2020
Figure 6-9: Global - Number of New Prostate Cancer Cases (Million), 2012 & 2020
Figure 6-10: Global - Forecast for New Prostate Cancer Cases by Region (%), 2020
Figure 8-1: Fresenius Kabi - Sales & Net Income (Billion US$), 2012 & 2013
Figure 8-2: Fresenius Kabi - Revenue Share by Region (%), 2013
Figure 8-3: Fresenius Kabi - Revenue Share by Business Segment (%), 2013
Figure 8-4: Actavis - Sales & Net Income (Billion US$), 2012 & 2013
Figure 8-5: Actavis - Revenue Share by Region (%), 2013
Figure 8-6: Actavis - Revenue Share by Business Segment (%), 2013
Figure 8-7: Hospira - Sales & Net Income (Billion US$), 2012 & 2013
Figure 8-8: Hospira - Revenue Share by Region (%), 2013
Figure 8-9: Hospira - Revenue Share by Business Segment (%), 2013
Figure 8-10: Teva - Sales & Net Income (Billion US$), 2012 & 2013
Figure 8-11: Teva - Revenue Share by Region (%), 2013
Figure 8-12: Hospira - Revenue Share by Business Segment (%), 2013
Figure 8-13: Mylan - Sales & Net Income (Billion US$), 2012 & 2013
Figure 8-14: Mylan - Revenue Share by Region (%), 2013
Figure 8-15: Mylan - Revenue Share by Business Segment (%), 2013
Figure 8-16: Sun Pharma - Sales & Net Income (Billion US$), 2012-13/ 2013-14
Figure 8-17: Sun Pharma - Revenue Share by Business Segment (%), 2013-14

List of Tables:

Table 3-1: Most Prevalent Types of Cancer
Table 3-2: Top 10 Countries with Highest Cancer Prevalence Rates
Table 5-1: List of Companies Dealing in Generic Arimidex
Table 5-2: Cost Comparison of Generics and Branded Arimidex (Anastrozole)
Table 5-3: List of Companies Dealing in Generic Femara
Table 5-4: Cost Comparison of Generics and Branded Femara (Letrozole)
Table 5-5: List of Companies Dealing in Generic Hycamtin
Table 5-6: List of Companies Dealing in Generic Xeloda
Table 5-7: Cost Comparison of Generics and Branded Xeloda (Capecitabine)
Table 5-8: List of Companies Dealing in Generic Camptosar
Table 5-9: Cost Comparison of Generics and Branded Camptosar (Irinotecan Hydrochloride)
Table 5-10: List of Companies Dealing in Generic Gemzar (Gemcitabine Hydrochloride)
Table 5-11: Cost Comparison of Generics and Branded Gemzar (Gemcitabine Hydrochloride)
Table 5-12: List of Companies Dealing in Generic Navelbine (Vinorelbine)
Table 5-13: Cost Comparison of Generics and Branded Navelbine (Vinorelbine)
Table 5-14: List of Companies Dealing in Generic Platinol (Cisplatin)
Table 5-15: List of Companies Dealing in Generic Taxol (Paclitaxel)
Table 5-16: Cost Comparison of Generics and Branded Taxol (Paclitaxel)
Table 5-17: List of Companies Dealing in Generic Taxotere (Docetaxel)
Table 5-18: Cost Comparison of Generics and Branded Taxotere (Docetaxel)
Table 6-1: Top 10 Countries by Lung Cancer Incidences (2012)
Table 6-2: Global - Key Lung Cancer Drugs and Patent Expiry Status
Table 6-3: Top 10 Countries by Breast Cancer Incidences (2012)
Table 6-4: Global - Key Breast Cancer Drugs and Patent Expiry Status
Table 6-5: Top 10 Countries by Colorectal Cancer Incidences (2012)
Table 6-6: Global - Key Colorectal Cancer Drugs and Patent Expiry Status
Table 6-7: Top 10 Countries by Stomach Cancer Incidences (2012)
Table 6-8: Global - Key Stomach Cancer Drugs and Patent Expiry Status
Table 6-9: Top 10 Countries by Prostate Cancer Incidences (2012)
Table 6-10: Global - Key Prostate Cancer Drugs and Patent Expiry Status
Table 7-1: Global - Key Cancer Drugs and Patent Expiry Status
Table 8-1: Fresnius Kabi Pharmaceuticals - Key Cancer Generic Drugs
Table 8-2: Actavis - Key Cancer Generic Drugs
Table 8-3: Hospira - Key Cancer Generic Products
Table 8-4: Teva Pharmaceuticals - Key Cancer Generic Drugs
Table 8-5: Mylan - Key Cancer Generic Drugs
Table 8-6: Sun Pharmaceuticals - Key Cancer Generic Drugs